Ewa Zarzycka

593 total citations · 1 hit paper
23 papers, 355 citations indexed

About

Ewa Zarzycka is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ewa Zarzycka has authored 23 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 11 papers in Genetics and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ewa Zarzycka's work include Acute Myeloid Leukemia Research (11 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Ewa Zarzycka is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Ewa Zarzycka collaborates with scholars based in Poland, Italy and China. Ewa Zarzycka's co-authors include Christian Récher, Pau Montesinos, Diego A. Gianolio, Jianan Hui, Stéphane de Botton, Andre C. Schuh, Hartmut Döhner, Michael Heuser, Rodrigo T. Calado and Jianxiang Wang and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Ewa Zarzycka

18 papers receiving 350 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia

2022 295 citations Pau Montesinos, Christian Récher et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ewa Zarzycka Poland	6	251	179	71	58	52	23	355
Curtis A. Lachowiez United States	10	267 1.1×	168 0.9×	88 1.2×	48 0.8×	53 1.0×	35	319
Federica Cattina Italy	9	187 0.7×	136 0.8×	80 1.1×	41 0.7×	51 1.0×	35	282
Ghayas C. Issa United States	8	219 0.9×	118 0.7×	86 1.2×	54 0.9×	44 0.8×	30	291
Adil S. A. Al Hinai Netherlands	6	227 0.9×	118 0.7×	90 1.3×	42 0.7×	29 0.6×	7	299
Ahmad Antar Lebanon	6	269 1.1×	135 0.8×	55 0.8×	51 0.9×	43 0.8×	13	333
Paul Cahalin United Kingdom	8	433 1.7×	198 1.1×	104 1.5×	74 1.3×	142 2.7×	14	460
Madlen Jentzsch Germany	13	405 1.6×	111 0.6×	104 1.5×	65 1.1×	132 2.5×	61	469
Qi Gao United States	9	180 0.7×	118 0.7×	67 0.9×	126 2.2×	51 1.0×	30	308
Melissa Rijken Netherlands	4	260 1.0×	117 0.7×	100 1.4×	34 0.6×	39 0.8×	13	326

Countries citing papers authored by Ewa Zarzycka

Since Specialization

Citations

This map shows the geographic impact of Ewa Zarzycka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ewa Zarzycka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ewa Zarzycka more than expected).

Fields of papers citing papers by Ewa Zarzycka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ewa Zarzycka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ewa Zarzycka. The network helps show where Ewa Zarzycka may publish in the future.

Co-authorship network of co-authors of Ewa Zarzycka

This figure shows the co-authorship network connecting the top 25 collaborators of Ewa Zarzycka. A scholar is included among the top collaborators of Ewa Zarzycka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ewa Zarzycka. Ewa Zarzycka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Özcan, Muhıt, Ryan D. Cassaday, Ewa Zarzycka, et al.. (2025). Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study. Haematologica. 110(8). 1736–1746. 1 indexed citations

Montesinos, Pau, Dylan M. Marchione, Christian Récher, et al.. (2025). Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1 -mutated AML. Blood Advances. 9(20). 5177–5189. 3 indexed citations

Short, Nicholas J., Agnieszka Wierzbowska, Thomas Cluzeau, et al.. (2024). Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia. Leukemia & lymphoma. 66(3). 458–468. 1 indexed citations

Bołkuń, Łukasz, Joanna Drozd‐Sokołowska, Ewa Zarzycka, et al.. (2024). A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience. Frontiers in Oncology. 14. 1395992–1395992.

Zarzycka, Ewa, et al.. (2024). Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia. Leukemia & lymphoma. 65(9). 1292–1302. 1 indexed citations

Döhner, Hartmut, Pau Montesinos, Ewa Zarzycka, et al.. (2023). P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE. HemaSphere. 7(S3). e83152da–e83152da.

Zarzycka, Ewa, et al.. (2023). Isolated Progression of Multiple Myeloma into the Extramedullary Plasmacytoma of Dura Mater: A Case Report and Review of the Literature. Biomedicines. 11(4). 1225–1225. 1 indexed citations

Prejzner, Witold, Alicja Sadowska‐Klasa, Ewa Zarzycka, et al.. (2023). The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review. Frontiers in Oncology. 13. 1228481–1228481. 4 indexed citations

Rückemann-Dziurdzińska, Katarzyna, Justyna Sakowska, Maciej Zieliński, et al.. (2023). Long-term allogeneic hematopoietic cells transplantation survivors proinflammatory cytokine profile compared to their respective donors and immunophenotype differences depending on GvHD history and infection status. Acta Haematologica Polonica. 1 indexed citations

10.

Botton, Stéphane de, Pau Montesinos, Ewa Zarzycka, et al.. (2023). Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.. Journal of Clinical Oncology. 41(16_suppl). 7012–7012. 12 indexed citations

11.

Sakowska, Justyna, Maciej Zieliński, Agnieszka Piekarska, et al.. (2022). Ageing-resembling phenotype of long-term allogeneic hematopoietic cells recipients compared to their donors. Immunity & Ageing. 19(1). 51–51. 1 indexed citations

12.

Zarzycka, Ewa, et al.. (2022). The Application of Copper and Silver Nanoparticles in the Protection of Fagus sylvatica Wood against Decomposition by Fomes fomentarius. Forests. 13(10). 1724–1724. 5 indexed citations

13.

Döhner, Hartmut, Dylan M. Marchione, Sung Choe, et al.. (2022). Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML Treated with Ivo+AZA in the AGILE Study. Blood. 140(Supplement 1). 539–542. 3 indexed citations

14.

Zarzycka, Ewa, et al.. (2022). Punkty wyjścia. Z Ewą Zarzycką o sztuce performansu, rysunkach i tekstach w transmedialnym archiwum rozmawiają Marta Baron-Milian i Aleksander Wójtowicz. 19(1). 1–13.

15.

Montesinos, Pau, Christian Récher, Susana Vives, et al.. (2022). Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia. New England Journal of Medicine. 386(16). 1519–1531. 295 indexed citations breakdown →

16.

Montesinos, Pau, Christian Récher, Susana Vives, et al.. (2021). AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation. Blood. 138(Supplement 1). 697–697. 7 indexed citations

17.

Göller, Kristina, Jan Maciej Zaucha, Ewa Zarzycka, et al.. (2021). RVU120 (SEL120) CDK8/19 Inhibitor - a Drug Candidate for the Treatment of MDS Can Induce Erythroid Differentiation. Blood. 138(Supplement 1). 1518–1518.

18.

Lewicka, Ewa, et al.. (2020). Assessment of dabigatran plasma concentration may improve the safety of anticoagulation in patients treated with ibrutinib with concomitant atrial fibrillation. Kardiologia Polska. 78(5). 454–457. 2 indexed citations

19.

Zarzycka, Ewa, et al.. (2015). Seismicity of Czorsztyn Lake Region: A Case of Reservoir Triggered Seismic Process?. Acta Geophysica. 63(4). 1080–1089. 10 indexed citations

20.

Zarzycka, Ewa, et al.. (2006). Czynniki wpływające na jakość życia u pacjentów z kardiowerterem-defibrylatorem serca. Via Medica Journals. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact